Biotech Startup Absci Debuts on Nasdaq

By Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
Published on July 24, 2021

Absci, a Vancouver-based biotech startup, has been valued at $2 billion after debuting in Nasdaq via an Initial Public Offering that caused shares’ price to increase by over 35% during the first day of listing.

By the end of Thursday, Absci had raised about $200 million that the company will use to continue developing its AI-powered technology to boost drug production while reducing costs of production.

The $2 billion valuation was enough to make Absci one of the most valuable public companies in the area, surpassing giants like NW Natural, nLight, Schnitzer Steel, or Greenbrier.

Absci CEO Sean McClain referred to this success by stating:

“I firmly believe that we can make this region a successful synthetic biology hub. We realized that we could raise capital here in the region as well as recruit top talent, so we decided to stay and grow here in the region.”

After having founded the startup over a decade ago in his parent’s home in Sherwood, McClain’s startup grew to employ more than 160 employees and generate more than $4.8 million in revenue in 2020.

The startup is focused on disrupting the protein-based pharmaceutical industry by harvesting the power of its software to improve effectiveness in the treatment of certain conditions. This approach allowed the company to raise more than $230 million prior to the IPO, having important pharmaceutical companies like Merck fund the startup.

While the revenue generated by the startup is still small for its valuation, the potential of its technology has caused investors to jump over the opportunity to invest at a time when the health industry’s shortcomings were highlighted by the recent epidemic.

The success of the biotech startup will depend on its ability to grow its number of drug candidate programs using its offerings, as it will show the technology’s potential. However, with investors like Merck partnering with the startup, Absci stands to generate millions of dollars in revenue for its investors over the next few years.

By Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team

Nicholas Ross Say is a news desk editor at Grit Daily. An award-winning journalist, he covers the daily startup beat. He grew up in Ann Arbor, Michigan and has lived in South America and South East Asia. At present, Nicholas lives in Southern Vietnam where the Sun shines, and the noodles flow like wine. He's written for Blockonomi and Coin Journal, among others.

Read more

More articles by Nicholas Say


Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 12, 2021

Genetics Startup iECURE Closes $50 mln Series A Funding Round

social media
Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 12, 2021

Bipartisan Social Media Platform Developed By Students Launch Beta Version

Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 12, 2021

Robotics Startup Agile Robots Secures $220 mln in Funding

Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 12, 2021

GreenTech Startup Solugen Closes $350 mln Series C Financing Round

Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 11, 2021

Nutrition Startup Teatis Closes $1 mln Seed Funding Round

Nicholas Say Nicholas Say has been verified by Muck Rack's editorial team
on September 11, 2021

Education Startup Leap Secures $55 mln In Series C Funding

More GD News